without passing judgement on the content reschard, the case studies presented on that site show no discussion of:
-follow up therapy completed,
-longevity of outcomes, -
-discussion of side effects,
-probability of quality outcome,(obviously no discussion of unfavourable outcome)
- relation of offered treatment to previously completed unrelated treatments per patient, chemo etc
the expedient path that contemporary chinese medicine has taken as opposed to the more thorough western approach leaves the prospective client open to a world of subjectivity.
costs are listed at average 30-40k us, before extras including transfusions, albumin. 60 days in china also required, often longer.
it is however of course interesting reading, thank you for the link reschard.
- Forums
- ASX - By Stock
- IMM
- chinese competitor dendritic-cell therapy
chinese competitor dendritic-cell therapy, page-4
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
34.0¢ |
Change
-0.005(1.45%) |
Mkt cap ! $493.8M |
Open | High | Low | Value | Volume |
34.0¢ | 34.0¢ | 32.5¢ | $1.317M | 3.935M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 73996 | 33.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
34.0¢ | 836970 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
10 | 67679 | 0.325 |
11 | 193888 | 0.320 |
1 | 25000 | 0.315 |
2 | 35400 | 0.310 |
5 | 103336 | 0.305 |
Price($) | Vol. | No. |
---|---|---|
0.340 | 674262 | 1 |
0.345 | 179754 | 4 |
0.350 | 527571 | 5 |
0.355 | 30000 | 1 |
0.360 | 51000 | 2 |
Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |